RETRACTED ARTICLE: Degradation of long non-coding RNA-CIR decelerates proliferation, invasion and migration, but promotes apoptosis of osteosarcoma cells

Abstract

BackgroundOver the years, long non-coding RNAs (lncRNAs) have been clarified in malignancies, this research was focused on the role of lncRNA cartilage injury-related (lncRNA-CIR) in osteosarcoma cells.MethodsLncRNA-CIR expression in osteosarcoma tissues and cells, and adjacent normal tissues and normal osteoblasts was determined, then the relations between lncRNA-CIR expression and the clinicopathological features, and between lncRNA-CIR expression and the prognosis of osteosarcoma patients were analyzed. Moreover, the MG63 and 143B cells were treated with silenced or overexpressed lncRNA-CIR, and then the proliferation, invasion, migration and apoptosis of the cells were evaluated by gain- and loss-of-function approaches. The tumor growth, and proliferation and apoptosis of osteosarcoma cells in vivo were observed by subcutaneous tumorigenesis in nude mice.ResultsWe have found that lncRNA-CIR was up-regulated in osteosarcoma tissues and cells, which was respectively relative to adjacent normal tissues and normal osteoblasts. The expression of lncRNA-CIR was evidently correlated with disease stages, distant metastasis and differentiation of osteosarcoma patients, and the high expression of lncRNA-CIR indicated a poor prognosis. Furthermore, the reduction of lncRNA-CIR could restrict proliferation, invasion and migration, but promote apoptosis of osteosarcoma cells in vitro. Meanwhile, inhibited lncRNA-CIR also restrained tumor growth and osteosarcoma cell proliferation, whereas accelerated apoptosis of osteosarcoma cells in vivo.ConclusionWe have found in this study that the inhibited lncRNA-CIR could decelerate proliferation, invasion and migration, but accelerate apoptosis of osteosarcoma cells, which may provide a novel target for osteosarcoma treatment.

RETRACTED: LINC00174 Facilitates Cell Proliferation, Cell Migration and Tumor Growth of Osteosarcoma via Regulating the TGF-β/SMAD Signaling Pathway and Upregulating SSH2 Expression

“…For example, downregulation of NCK-AS1 modulates cell resistance to cisplatin in OS (Cheng et al, 2019). LncRNA-CIR accelerates OS cell proliferation and represses cell apoptosis (Liu et al, 2019). Moreover, HIF-1α induced lncRNA FOXD2-AS1 could promote OS progression by repressing the expression of p21 (Ren et al, 2019).…”

MicroRNA-582-3p targeting ribonucleotide reductase regulatory subunit M2 inhibits the tumorigenesis of hepatocellular carcinoma by regulating the Wnt/β-catenin signaling pathway

“…Interestingly, RRM2 is involved in miR-520a-mediated inactivation of the Wnt/β-catenin pathway during the development of non-small cell lung cancer [ 37 ]. RRM2 silencing has been suggested to inactivate the Wnt/β-catenin signaling pathway by increasing GSK-3β phosphorylation in multiple myeloma [ 38 ]. Our hypothesis that there is an interplay between miR-582-3p and RRM2 was confirmed by our findings, which demonstrated that miR-582-3p suppresses RRM2 expression to attenuate its carcinogenic effects.…”

Long non-coding RNA-PCGEM1 contributes to prostate cancer progression by sponging microRNA miR-129-5p to enhance chromatin licensing and DNA replication factor 1 expression

“…lncRNAs play a crucial role in multiple processes that modulate gene expression, and their transcription can lead to gene silencing or gene activation [ 29 , 30 ]. It has been revealed that lncRNAs participate in the biological processes of many diseases, including cancer, regulating cell proliferation, apoptosis, differentiation, and metastasis [ 31 , 32 ]. For example, elevated levels of lncRNA ROR in PCa tissue are associated with late tumor staging, lymph node or distant metastasis, and modulation of the AKT pathway to promote malignant proliferation of PCa cells [ 33 ].…”